Bridgebio Pharma Inc. (bbio 2.25 02/01/29)
13F holders, Q4 2024 (December 31)3holders −1
0new positions
1sold out
$1.02avg. 13F price*
At the end of Q4 2024, 3 institutions reported holding Bridgebio Pharma Inc. (bbio 2.25 02/01/29) in their 13F filings, down 1 from Q3 2024. 0 opened new positions and 1 sold out. The largest holders were Ewing Morris & Co. Investment Partners Ltd. ($2.5M), BNP PARIBAS ASSET MANAGEMENT Holding S.A. ($2.1M) and Sei Investments Co. ($133K).
- Company
- Bridgebio Pharma Inc. (bbio 2.25 02/01/29)
- CUSIP
- 10806XAD4
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $2.5M |
All 13F filers, Q3 2024 → Q4 2024: 2,937,000 shares sold, net −2,937,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Ewing Morris & Co. Investment Partners Ltd. | 0.86% | No change | 2,000,000 | $2.5M |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.01% | No change | 2,500,000 | $2.1M |
| Sei Investments Co. | 0.00% | No change | 156,000 | $133K |
"% of holder's portfolio" is BRIDGEBIO PHARMA INC (BBIO 2.25 02/01/29)'s weight in each manager's 13F, not the share of Bridgebio Pharma Inc. (bbio 2.25 02/01/29) the manager owns.